FDA slaps hold on Cellectis’ off-the-shelf myeloma CAR-T trial after patient death July 7, 2020 Auto Bot BioPharma, biopharma nl, cancer, CAR-T, cell therapy, Food and Drug Administration, France, multiple myeloma, Paris 0 The patient, who had been enrolled in the Phase I study at the higher dose level of UCARTCS1A, suffered a cardiac arrest, the causes of which are under investigation, the company said.